

Managing and maintaining diagnosis in the community

—

Sustaining gains

David Bell


WHO – Global Malaria Programme

International Malaria Colloquium 2010 (IMC 2010)


Bangkok. December 2010



Evolution of parasite based diagnosis in malaria in Senegal public health services 2007-2009.




WHO-FIND malaria RDT evaluation programme




WHO malaria RDT product testing Round 1 & 2 results

Rnd 1 (2008) 41 products
 Rnd 2 (2009) 29 products
 Rnd 3 (2010) 50 products

P. falciparum



Lot Testing



2006: 41 lots


2007: 81 lots

2008: 167 lots

2009: 196 lots

2010: +++

(?15% of public sector procurement)



Future lot-testing panels



Recombinant-based panels, suitable for use at NMCP level.

Trials in 2011

Community/clinic-level monitoring of RDT quality




Still a gap, but can:

- **Compare routinely with microscopy at sentinel sites (often difficult, works if good microscopy)**
- **Withdraw of RDTs from field for lab testing (working in some situations, but logistically difficult)**

Future: Positive Control Wells

- **Under development by FIND, WHO, and partners**
- **Field implementation trials 2011**



Training and instructions - Zambia






Suite of products:

Job-aid


Training manual

Photographic result guide

Proficiency tests



12 month follow-up 2008-9: Performance of 'critical steps'






Courtesy: Malaria Consortium

**Accurate malaria diagnosis can
now be accessible to all.**



Success. What next?



Successful intervention

10 cases per month.

Malaria now down from 1st to 16th district health priority....other disease priorities are more urgent

But the mosquitoes and the people are still there...

We have the tools to identify and manage malaria as a common disease

We need new tools and strategies to manage malaria as a rare disease

Challenges for low-prevalence malaria

- **Loss of interest**
 - Few deaths
 - Little publicity
- **Less finance available?**
 - Priorities elsewhere (eg. GF, DFID strategy)
 - Fall-out from financial crisis
- **Conditions for transmission remain**
 - Vectors
 - People / immigration
 - LLINs will wear out after 3-5 years

Maintaining very low transmission / elimination with current tools: Zanzibar

The costs of keeping $R_0 < 1$

Zanzibar elimination feasibility assessment
(with and without bednets long-term)

- Population immunity drops
- Immigrants from malaria-endemic areas continue to arrive
- Vectors remain

Who would pay for this when the excitement of elimination is over?

FIGURE 30: AVERAGE COST PER YEAR FOR THE DIFFERENT STAGES OF AN ELIMINATION PROGRAM WITH LLIN'S KEPT AT > 75% EFFECTIVE COVERAGE COMPARED TO SUSTAINED CONTROL





FIGURE 31: AVERAGE COST PER YEAR FOR THE DIFFERENT PHASES OF AN ELIMINATION PROGRAM WITH NO LLIN'S AFTER 2030, COMPARED TO SUSTAINED CONTROL



Very low prevalence settings in resource-limited countries

- **Unlikely to sustain microscopy competence or infrastructure when slides ~always negative**
- **Difficult to maintain financing for RDTs for all febrile cases if results are nearly always negative**
- **Hard to maintain priority and enthusiasm within the MoH and within communities**
- **Unlikely to maintain adequate donor funding for conventional programme**

But



- **Still high probability of focal transmission and re-introduction outbreaks**

How to keep tools and workers in place?

- **Diversify**
 - Malaria an essential part of broader effort (IMCI, EPI, new strategies for non-malarial febrile illness)
- **Focus efforts to areas of need**
 - New tools and strategies
 - Identify priority areas
 - Improve surveillance with real-time information
 - Need to detect ‘reservoirs’ that are maintaining transmission
 - Change funding structure to allow more flexibility
- **Programmes will have to be increasingly self-contained**
 - Communities will have to want to prioritize malaria
 - Can’t be imposed from outside
 - Need good communication


Untreated *P. falciparum* infections (Hidden reservoirs)

Examples of long-term course of untreated *P. falciparum* infections



Source: *Therapeutic malaria in man: Sporozoite and blood-induced infections with Plasmodium falciparum.*
William E Collins and Geoffrey M Jeffrey.
Unpublished.

Untreated *P. falciparum* infections



Asymptomatic reservoir

Must be detected to assess true prevalence of parasitaemia, prevent re-introduction


Must detect in field if case finding and treatment (FSAT) is employed

How common is sub-microscopic infection?

Meta-analysis of 72 studies of microscopy vs PCR

High transmission areas: Micro + 74.5% when PCR prevalence >75%


Low transmission areas: Micro + 12.0% when PCR prevalence <10%.



Results in MSAT/FSAT test in Phnom Damban, Cambodia

	1st test Nov. 08	2nd test May 09	3rd test May 10
Microscopy	22/416 5.2%	34/512 6.6%	5/375 1.3%
PCR	57/416 13.7%	49/512 9.6%	13/375 3.5%

Gametocyte infectivity



Potential strategies in countries approaching elimination

Stratification based on surveys and surveillance

In regions with significant transmission:

- 1. Continued case management diagnostic tools for symptomatic cases in high-priority areas (RDTs / microscopy)**


In regions with little or no transmission:

- 2. A low-cost screening tool that can rapidly survey large areas to identify hot-spots of continued transmission**
- 3. A highly sensitive field diagnostic tool to screen all people in identified hot-spots to detect and treat hidden reservoirs**

Survey tools to detect continuing transission



Serology

Screen large populations for signs of recent malaria transmission



Greece 1974: 15 years post E

Mauritius 1973: 5 years post E



Measuring transmission through serology


The rate of sero-conversion is linked to the transmission intensity (NE Tanzania)

Emmao 1800m

Handei 1300m

Tewe 900m

Mn'galo 400m



Finding and eliminating hidden parasite reservoirs in transmission foci

Will need field molecular diagnostic tools to detect very low parasite densities...

Need to determine where this is needed, where it is not

Eg. IPC model (Cambodia)




High through put PCR with rapid communication to field

Eg. Malaria LAMP

Detects 1 parasite/ μ L

Potential for district / clinic level use

Find and treat malaria 'carriers'




Diagnostics R&D funding

The needle in the pie chart


Malaria R&D research funding 2007

Top 12 funders:
\$484 M

- Drug development \$214M
- Diagnostics \$1.6M




Current maps of malaria incidence



Possible future for malaria??

Wild Poliovirus*, 25 Dec 2007 – 24 Jun 2008



*Excludes viruses detected from environmental surveillance and vaccine derived polio viruses.

Data in WHO HQ as of 24 June 2008

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
© WHO 2008. All rights reserved

Thank you

Acknowledgements:

- **FIND**
- **TDR (Jane Cunningham)**
- **LSHTM (Chris Drakeley)**
- **Malaria Consortium (Helen Counihan)**
- **URC (Steve Harvey)**

